Nurix Therapeutics Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Nurix Therapeutics, Inc. (NRIX) - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2025Nov 2024Nov 2023Nov 2022Nov 2021Nov 2020
Operating Activities
Net Income-264.46-193.57-143.95-180.36-117.19-43.24
Depreciation & Amortization18.8615.1312.259.615.282.18
Stock Based Compensation37.9733.9333.6728.1315.804.30
Change in Working Capital-31.60-18.4020.12-19.029.1136.41
Change in Accounts Receivable0.000.000.006.00-6.00-7.50
Change in Accounts Payable-0.635.211.610.091.591.23
Change in Other Working Capital-30.974.94-1.011.52-4.37-1.66
Other Operating Activities-10.230.2921.980.2010.664.30
Net Cash from Operating Activities-249.47-172.58-81.37-159.81-84.37-0.08
Investing Activities
Capital Expenditures-14.00-9.27-8.40-12.24-5.66-4.55
Purchases of Investments-455.69-248.4476.7039.44-102.59-249.85
Sales/Maturities of Investments617.54459.51-246.3339.44-102.59-249.85
Net Cash from Investing Activities147.85-257.7168.3027.20-108.25-254.40
Financing Activities
Common Stock Issued238.64485.683.2222.43164.13239.42
Common Stock Repurchased0.00-0.020.000.000.000.00
Other Financing Activities0.007.170.0094.76-10.24-20.65
Net Cash from Financing Activities238.64485.673.22117.19153.88339.02
Summary
Effect of Forex Changes on Cash-0.070.000.000.000.000.00
Net Change in Cash137.0355.37-9.85-15.42-38.7384.54
Cash at Beginning of Period110.0055.5365.3880.79119.5334.99
Cash at End of Period247.93110.90-327.7364.47119.36119.36
Free Cash Flow-263.47-181.86-89.77-172.05-90.03-4.63
Supplemental Disclosures
Income Taxes Paid0.000.000.000.000.480.00